Cargando…

Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer

Anal cancer and the related treatment are generally known to affect patients’ quality of life. The aim of this study was to assess self-reported quality of life (QoL) of anal cancer patients after combined radiation and chemotherapy, and to identify patient-, disease-, and therapy-related factors as...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauter, Christina, Peeken, Jan C., Borm, Kai, Diehl, Christian, Münch, Stefan, Combs, Stephanie E., Dapper, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924204/
https://www.ncbi.nlm.nih.gov/pubmed/35292732
http://dx.doi.org/10.1038/s41598-022-08525-1
_version_ 1784669799523024896
author Sauter, Christina
Peeken, Jan C.
Borm, Kai
Diehl, Christian
Münch, Stefan
Combs, Stephanie E.
Dapper, Hendrik
author_facet Sauter, Christina
Peeken, Jan C.
Borm, Kai
Diehl, Christian
Münch, Stefan
Combs, Stephanie E.
Dapper, Hendrik
author_sort Sauter, Christina
collection PubMed
description Anal cancer and the related treatment are generally known to affect patients’ quality of life. The aim of this study was to assess self-reported quality of life (QoL) of anal cancer patients after combined radiation and chemotherapy, and to identify patient-, disease-, and therapy-related factors associated with QoL. A total of 94 patients treated with definitive chemoradiation for anal cancer at our institution in the period from 2004 to 2018 were identified from our database. QoL was assessed in the remaining 52 patients using the EORTC QLQ-C30 questionnaire (cancer-specific QoL) and the newly developed anal cancer module QLQ-ANL27 (site-specific QoL). Differences in QoL between anal cancer patients and a German age and sex adjusted reference population were examined. The median follow-up was 71 months (range, 7–176). In the cancer-specific QoL module, the anal cancer cohort presented with significantly lower scores in role (− 12.2 points), emotional (− 6.6 points), and social functioning (− 6.8 points), but higher scores in diarrhea (+ 36.3 points) and constipation (+ 13.3 points) than the German reference population. There were no significant differences in disease- or therapy-related factors, but age greater than 70 years and a follow-up time greater than 71 months had a negative impact on global QoL. As for the site-specific QoL, patients with a tumor relapse showed significantly higher symptom scores than patients with a complete clinical remission in all scales except of micturition frequency. Compared to 3D conformal radiotherapy, IMRT treatment seemed to improve non-stoma bowel function (+ 23.3 points), female sexual functioning (+ 24.2 points), and came along with less scores in the symptom scales pain (− 35.9 points), toilet proximity (− 28.6 points), and cleanliness (− 26.2 points). Most of the functional scores of anal cancer patients were lower compared to the general German population, but did not seem to affect the general QoL. Fatigue, physical, and role functioning had the strongest impact on global QoL causing psychological symptoms as important as physical.
format Online
Article
Text
id pubmed-8924204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89242042022-03-17 Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer Sauter, Christina Peeken, Jan C. Borm, Kai Diehl, Christian Münch, Stefan Combs, Stephanie E. Dapper, Hendrik Sci Rep Article Anal cancer and the related treatment are generally known to affect patients’ quality of life. The aim of this study was to assess self-reported quality of life (QoL) of anal cancer patients after combined radiation and chemotherapy, and to identify patient-, disease-, and therapy-related factors associated with QoL. A total of 94 patients treated with definitive chemoradiation for anal cancer at our institution in the period from 2004 to 2018 were identified from our database. QoL was assessed in the remaining 52 patients using the EORTC QLQ-C30 questionnaire (cancer-specific QoL) and the newly developed anal cancer module QLQ-ANL27 (site-specific QoL). Differences in QoL between anal cancer patients and a German age and sex adjusted reference population were examined. The median follow-up was 71 months (range, 7–176). In the cancer-specific QoL module, the anal cancer cohort presented with significantly lower scores in role (− 12.2 points), emotional (− 6.6 points), and social functioning (− 6.8 points), but higher scores in diarrhea (+ 36.3 points) and constipation (+ 13.3 points) than the German reference population. There were no significant differences in disease- or therapy-related factors, but age greater than 70 years and a follow-up time greater than 71 months had a negative impact on global QoL. As for the site-specific QoL, patients with a tumor relapse showed significantly higher symptom scores than patients with a complete clinical remission in all scales except of micturition frequency. Compared to 3D conformal radiotherapy, IMRT treatment seemed to improve non-stoma bowel function (+ 23.3 points), female sexual functioning (+ 24.2 points), and came along with less scores in the symptom scales pain (− 35.9 points), toilet proximity (− 28.6 points), and cleanliness (− 26.2 points). Most of the functional scores of anal cancer patients were lower compared to the general German population, but did not seem to affect the general QoL. Fatigue, physical, and role functioning had the strongest impact on global QoL causing psychological symptoms as important as physical. Nature Publishing Group UK 2022-03-15 /pmc/articles/PMC8924204/ /pubmed/35292732 http://dx.doi.org/10.1038/s41598-022-08525-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Sauter, Christina
Peeken, Jan C.
Borm, Kai
Diehl, Christian
Münch, Stefan
Combs, Stephanie E.
Dapper, Hendrik
Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
title Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
title_full Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
title_fullStr Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
title_full_unstemmed Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
title_short Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
title_sort quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924204/
https://www.ncbi.nlm.nih.gov/pubmed/35292732
http://dx.doi.org/10.1038/s41598-022-08525-1
work_keys_str_mv AT sauterchristina qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer
AT peekenjanc qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer
AT bormkai qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer
AT diehlchristian qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer
AT munchstefan qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer
AT combsstephaniee qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer
AT dapperhendrik qualityoflifeinpatientstreatedwithradiochemotherapyforprimarydiagnosisofanalcancer